Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Tarjinder Sahota"'
Autor:
Iñaki F. Trocóniz, Benjamin Ribba, Salvador Martín-Algarra, Marta Moreno-Jiménez, José-María López-Picazo, Tarjinder Sahota, Núria Buil-Bruna
LDH (upper panels) and NSE (lower panels) individual log-transformed concentration-time profiles from training dataset (left panels) and external dataset (right panels). Thick lines are loess smooth of the data and dashed gray lines represent the thr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2abc27ca76154c40adaaffa279d1c292
https://doi.org/10.1158/0008-5472.22405782.v1
https://doi.org/10.1158/0008-5472.22405782.v1
Autor:
Iñaki F. Trocóniz, Benjamin Ribba, Salvador Martín-Algarra, Marta Moreno-Jiménez, José-María López-Picazo, Tarjinder Sahota, Núria Buil-Bruna
Legends for supplementary Figures S1, S2 and S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5eed515e6416c1eb1dffc9005e10c4
https://doi.org/10.1158/0008-5472.22405785.v1
https://doi.org/10.1158/0008-5472.22405785.v1
Autor:
Iñaki F. Trocóniz, Benjamin Ribba, Salvador Martín-Algarra, Marta Moreno-Jiménez, José-María López-Picazo, Tarjinder Sahota, Núria Buil-Bruna
Schematic view of the biomarker model and differential equations used to describe the model. Briefly, DISEASE is a latent variable that represents disease progression and drives LDH and NSE production. RT (radiotherapy) and CT (chemotherapy) each aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09dcc7aed1a49b8c852e29ec94451f58
https://doi.org/10.1158/0008-5472.22405779.v1
https://doi.org/10.1158/0008-5472.22405779.v1
Autor:
Iñaki F. Trocóniz, Benjamin Ribba, Salvador Martín-Algarra, Marta Moreno-Jiménez, José-María López-Picazo, Tarjinder Sahota, Núria Buil-Bruna
Prediction accuracy at the individual level of RECIST model: Predicted probabilities of progression (sorted in ascending order) during treatment (SCAN 1 and SCAN 2, in green and orange) and at the first two follow-up CT scans (in blue and red) for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff961f097f4adcb6a32edc8cce2bbd5
https://doi.org/10.1158/0008-5472.22405776.v1
https://doi.org/10.1158/0008-5472.22405776.v1
Autor:
Yan Li, Torbjörn Vik, Dana Ghiorghiu, Corina Dota, Remy B. Verheijen, Stephen Walker, Ghada F. Ahmed, Tarjinder Sahota, Ronald Goldwater, Anders Mellemgaard, Weili Yan
Publikováno v:
Clinical Pharmacology in Drug Development. 10:521-534
Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor. This randomized, double-blind, 3-way, crossover phase 1 study of savolitinib versus moxifloxacin (positive control) and placebo-evaluated ef
Autor:
Chappell, Carlos Traynor, Tarjinder Sahota, Helen Tomkinson, Ignacio Gonzalez-Garcia, Neil Evans, Michael
Publikováno v:
Journal of Personalized Medicine; Volume 11; Issue 12; Pages: 1356
Missing data is a universal problem in analysing Real-World Evidence (RWE) datasets. In RWE datasets, there is a need to understand which features best correlate with clinical outcomes. In this context, the missing status of several biomarkers may ap
Autor:
Carlos Traynor, Tarjinder Sahota, Helen Tomkinson, Ignacio Gonzalez-Garcia, Neil Evans, Michael Chappell
Publikováno v:
Journal of Personalized Medicine, Vol 11, Iss 1356, p 1356 (2021)
Journal of Personalized Medicine
Journal of Personalized Medicine
Missing data is a universal problem in analysing Real-World Evidence (RWE) datasets. In RWE datasets, there is a need to understand which features best correlate with clinical outcomes. In this context, the missing status of several biomarkers may ap
Publikováno v:
The AAPS Journal. 23
Savolitinib is an oral, potent, and highly selective MET-tyrosine kinase inhibitor under investigation in various tumor types. A thorough QT study evaluated effects on QT interval after a 600-mg single savolitinib dose in healthy subjects. We report
Publikováno v:
The AAPS journal. 23(3)
Savolitinib is an oral, potent, and highly selective MET-tyrosine kinase inhibitor under investigation in various tumor types. A thorough QT study evaluated effects on QT interval after a 600-mg single savolitinib dose in healthy subjects. We report
Autor:
Lillian Castriotta, Alwin Schuller, Ryan E. Henry, Evan Barry, Michelle DuPont, Maryann San Martin, Celina M. D'Cruz, Tarjinder Sahota, Ghada F. Ahmed, Rhys D.O. Jones, Mike Grondine, Alexandra Borodovsky, Klas Petersson, Rana Anjum
Publikováno v:
British journal of pharmacologyREFERENCES. 178(3)
Background and purpose Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, potent, and highly MET receptor TK inhibitor. This series of studies aimed to develop a pharmacokinetic-pharmacodynamic (PK/PD) model to link inhibition of MET phosphorylat